Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors versus GLP-1 RAs, DPP-4 inhibitors<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Nov. 12, 2024 (HealthDay News) — For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reduction in recurrence, according to a study published online Oct. 30 in The BMJ<\/em>.<\/p>\n Natalie McCormick, Ph.D., from Massachusetts General Hospital in Boston, and colleagues emulated target trials comparing recurrence of nephrolithiasis among patients with preexisting nephrolithiasis initiating SGLT-2 inhibitors versus an active comparator. A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT-2 inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA), with a dipeptidyl peptidase-4 (DPP-4) inhibitor as an alternative comparator.<\/p>\n After inverse probability of treatment weighting, the researchers identified 1,924 recurrent nephrolithiasis events among 14,456 weighted patients who used an SGLT-2 inhibitor compared with 853 events among the 5,877 patients who used a GLP-1 RA (105.3 versus 156.4 per 1,000 person-years). The adjusted rate ratio was 0.67 and rate difference was \u221251 per 1,000 person-years. The absolute rate difference was 219 per 1,000 person-years among those with recently active nephrolithiasis. For nephrolithiasis events that required emergency department visits, hospital admissions, or procedures and when an SGLT-2 inhibitor was compared with a DPP-4 inhibitor, the protective associations persisted. Among patients with nephrolithiasis and concomitant gout, the protective associations also persisted (rate ratios, 0.67 and 0.63; rate differences, \u221253 and \u221262 per 1,000 person-years) compared with GLP-1 RAs and DPP-4 inhibitors, respectively.<\/p>\n “This class of drugs may be a useful addition to the current treatments for nephrolithiasis to simultaneously tackle the high burden of kidney stones and comorbidities, including gout,” the authors write.<\/p>\n Several authors disclosed ties to industry.<\/p>\n